The Technical Analyst
Adaptive Biotechnologies [ADPT]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Adaptive Biotechnologies Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
0.77% $2.63
America/New_York / 26 apr 2024 @ 11:38
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 381.59 mill |
| EPS: | -1.560 |
| P/E: | -1.690 |
| Earnings Date: | May 07, 2024 |
| SharesOutstanding: | 145.09 mill |
| Avg Daily Volume: | 1.697 mill |
| RATING 2024-04-25 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Sell | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -1.690 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.29x |
| Company: PE -1.690 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 2.39 - 2.90 ( +/- 9.75%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-12 | Neupert Peter M | Buy | 15 000 | Common Stock |
| 2024-03-12 | Neupert Peter M | Sell | 15 000 | Stock Option (right to buy) |
| 2024-03-04 | Pellini Michael J | Buy | 31 328 | Common Stock |
| 2024-03-04 | Pellini Michael J | Buy | 48 044 | Stock Option (right to buy) |
| 2024-03-04 | Owen Katey Einterz | Buy | 31 328 | Common Stock |
| INSIDER POWER |
|---|
| 61.58 |
| Last 100 transactions |
| Buy: 4 473 782 | Sell: 1 037 795 |
Forecast:
13:17 - $2.64
Live Trading Signals (every 1 min)
Forecast
1: 11:47 - $2.63
Forecast 2: 12:37 - $2.62
Forecast 3: 13:17 - $2.64
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $2.63 (0.77% ) |
| Volume | 0.301 mill |
| Avg. Vol. | 1.697 mill |
| % of Avg. Vol | 17.73 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ADPT
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | buy | $3.68 | N/A | Active |
|---|
ADPT
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ, a clinical diagnostic product for the detection and monitoring of minimal residual disease in patients with multiple myeloma, B cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia, as well as available as a CLIA-validated laboratory developed test for patients with other lymphoid cancers; and immunoSEQ T-MAP COVID for vaccine developers and researchers to measure the T-cell immune response to vaccines. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. It serves the life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
Latest Press Releases
2024-04-17 16:05:00 - Press Release
Adaptive Biotechnologies To Report First Quarter 2024 Financial Results On May 7, 2024
Seattle, april 17, 2024 (globe newswire) -- adaptive biotechnologies corporation (nasdaq: adpt), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the first quarter 2024 after market close on tuesday, may 7, 2024. company management will webcast a corresponding conference call beginning at 1:30 p.m. pacific time / 4:30 p.m. eastern time.
2024-04-02 16:05:00 - Press Release
Adaptive Biotechnologies Provides Strategic Review Update And Announces Preliminary First Quarter 2024 Revenue
Seattle, april 02, 2024 (globe newswire) -- adaptive biotechnologies corporation (nasdaq: adpt), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced a business update, including the conclusion of its recent strategic review, preliminary revenue for the first quarter ended march 31, 2024, and transition of the chief financial officer role. strategic review update after evaluating a number of potential opportunities as part of the strategic review, adaptive's management team and board of directors concluded that the current best outcome to maximize shareholder value is to operate the mrd and immune medicine businesses internally within adaptive while increasing their independence from one another by restructuring each business with dedicated resources and separate segment reporting.
2024-03-27 08:30:00 - Press Release
Adaptive Biotechnologies To Hold A Business Update Conference Call And Webcast On April 2, 2024
Seattle, march 27, 2024 (globe newswire) -- adaptive biotechnologies corporation (nasdaq: adpt), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will host a business update conference call and webcast after market close on tuesday, april 2, 2024 beginning at 1:30 p.m. pacific time / 4:30 p.m. eastern time.
2024-02-22 16:05:00 - Press Release
Adaptive Biotechnologies To Present At The Td Cowen 44th Annual Healthcare Conference
Seattle, feb. 22, 2024 (globe newswire) -- adaptive biotechnologies corporation (nasdaq: adpt), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming td cowen 44th annual healthcare conference in boston, ma.
2024-02-14 16:05:00 - Press Release
Adaptive Biotechnologies Reports Fourth Quarter And Full Year 2023 Financial Results
Seattle, feb. 14, 2024 (globe newswire) -- adaptive biotechnologies corporation (“adaptive biotechnologies”) (nasdaq: adpt), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the fourth quarter and full year ended december 31, 2023.
Latest News
2024-03-27 16:30:00 - InvestorPlace
The 7 Best Penny Stocks to Buy in Q2 2024
This month in March is a great time to pick up shares in these best penny stocks to buy. I chose the companies due to their strong fundamentals and potential for significant upside.
2024-02-22 16:05:00 - GlobeNewsWire
Adaptive Biotechnologies to Present at the TD Cowen 44th Annual Healthcare Conference
SEATTLE, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming TD Cowen 44th Annual Healthcare Conference in Boston, MA.
2024-02-14 21:51:03 - Seeking Alpha
Adaptive Biotechnologies Corporation (ADPT) Q4 2023 Earnings Call Transcript
2024-01-29 16:05:00 - GlobeNewsWire
Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2023 Financial Results on February 14, 2024
SEATTLE, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the fourth quarter and full year 2023 after market close on Wednesday, February 14, 2024. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
2023-12-27 16:05:00 - GlobeNewsWire
Adaptive Biotechnologies to Present at the 42nd Annual J.P. Morgan Healthcare Conference
SEATTLE, Dec. 27, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA.
2023-12-12 05:50:00 - The Motley Fool
Cathie Wood Is Loading Up on These 3 Small-Cap Stocks: Should You?
Adaptive Biotechnologies offers services related to immunosequencing and immune medicine. Genius Sports' sports data and technology is used by more than 400 sports organizations worldwide.
2023-12-05 07:30:00 - GlobeNewsWire
Adaptive Biotechnologies and Collaborators to Present More than 30 Abstracts Demonstrating the Actionability of clonoSEQ® MRD Testing in Blood Cancer Patient Care and Drug Development at the 65th ASH Annual Meeting
SEATTLE, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, together with its collaborators will present data from more than 30 abstracts demonstrating the actionability of Adaptive's next-generation sequencing (NGS)-based clonoSEQ® test in assessing minimal residual disease (MRD) in blood cancer patients at the 65th Annual Meeting of the American Society of Hematology (ASH), December 9-12 in San Diego, California. clonoSEQ is the only U.S. Food and Drug Administration (FDA)-cleared test to detect MRD in bone marrow from patients with multiple myeloma (MM) or B-cell acute lymphoblastic leukemia (B-ALL) and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL).
2023-11-09 22:01:03 - Seeking Alpha
Adaptive Biotechnologies Corporation (ADPT) Q3 2023 Earnings Call Transcript
Adaptive Biotechnologies Corporation (NASDAQ:ADPT ) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET Company Participants Karina Calzadilla - Head, IR Chad Robins - CEO and Co-founder Tycho Peterson - CFO Nitin Sood - Chief Commercial Officer, MRD Susan Bobulsky - Senior Vice President, Diagnostics, clonoSEQ Sharon Benzeno - Chief Commercial Officer, Immune Medicine Conference Call Participants Mark Massaro - BTIG Dan Brennan - TD Cowen David Westenberg - Piper Sandler Operator Thank you for standing by. At this time, I would like to welcome everyone to today's Adaptive Biotechnologies 2023 Third Quarter Earnings Call.
2023-09-27 17:05:00 - Seeking Alpha
Adaptive Biotechnologies: Not Quite There Yet, Growth Looks Priced
After a number of updates, there is no change in my investment rating for Adaptive Biotechnologies Corporation. Q2 FY'23 results showed mixed performance, with expectations for FY'23 sales to hit $215mm at the upper end of guidance. Technical indicators suggest a neutral posture for ADPT in the coming months.
2023-09-27 06:46:04 - Zacks Investment Research
Strength Seen in Adaptive Biotechnologies (ADPT): Can Its 9.5% Jump Turn into More Strength?
Adaptive Biotechnologies (ADPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.